According to MEI Pharma latest financial reports the cash on hand of MEIP is $100.69M, an decrease of -34.30% to 2022. At the end of 2022 company had $153.25M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $100.69M | -34.30% |
2022 | $153.25M | -0.11% |
2021 | $153.43M | -15.99% |
2020 | $182.63M | 145.18% |
2019 | $74.49M | - |